# TI Sigma Pharmacology Validation — Methods Paper Skeleton

**Status:** PARTIALLY FILLED (Pass 5, 2026-05-08) — sections 4, 5, and 9 now contain real specifics from the April 2026 BlissGene validation report; sections marked [BRACKETED — Brandon to confirm] still need Brandon's confirmation or additions; rest is structural skeleton.
**Author:** Brandon Charles Emerick (with Replit Agent draft assistance)
**Created:** 2026-05-08 (Pass 4); updated Pass 5 with real specifics from `pharma_simulator_validation_report.md`.
**Goal:** Upgrade the F-1 ("82% pharmacology accuracy") claim from INTERNAL — PENDING EXTERNAL REPLICATION to VERIFIED via Zenodo deposit + (eventually) journal submission.

---

## 1. Title

*Provisional:* "TI Sigma: A Consciousness-Coupled Pharmacological Simulator with Retrospective Validation Against Twelve Peer-Reviewed Studies of FAAH Inhibition, Serotonergic Augmentation, and Adjunctive Combinations"

## 2. Abstract (~250 words)

We present TI Sigma, a consciousness-coupled pharmacological simulator that predicts drug and supplement effects via a four-dimensional GILE state representation (Goodness, Intuition, Love, Environment) coupled to genetic, receptor-density, and consciousness-state parameters. Unlike population-statistics models, TI Sigma is individual-specific: predictions are conditioned on each subject's genetic profile (FAAH activity, COMT, CB1 receptor density, schizotypy SNP load), consciousness metrics (LCC, GILE baseline), and biometric data (HRV, EEG coherence). We retrospectively validate the simulator against twelve peer-reviewed pharmacological studies covering rat, mouse, and human RCT/case-study designs, spanning FAAH inhibition (URB597, PF-04457845, FAAH knockouts, the Jo Cameron FAAH-OUT case), serotonergic augmentation (saffron, 5-HTP), gut-brain axis (L. helveticus + B. longum probiotic), omega-3 EPA-dominant antidepressant effects, MTHFR-variant L-methylfolate adjunctive depression treatment, mitochondrial-biogenesis cognition (PQQ), and rapid antidepressant ketamine-lithium synergy. Directional accuracy was 12/12 = 100% (every TI prediction matched the empirical sign of the effect). Magnitude accuracy (within 2× of the empirical effect size) was 10/12 = 83.3%. The mean TI/empirical ratio was 1.20 — the simulator is approximately calibrated. We discuss limitations including: small N = 12 (each experiment is independent and peer-reviewed but the validation set is hand-curated), retrospective design (no train/test split since the design tests the simulator against published studies it did not see during construction), and the absence of a formally-computed linear-model baseline. Source code and the experiment-by-experiment computational record are deposited at [Zenodo URL forthcoming].

## 3. Background and Hypothesis

### 3.1 Background

Conventional pharmacology models predict mean responses across population samples, with prediction accuracy in the 40-60% range for individual responses (cited by `TI_PHARMACOLOGICAL_SIMULATOR_EMPIRICAL_VALIDATION.md` §1.1). TI Sigma inverts this: predictions are individual-specific, parameterized by the subject's genetic profile + consciousness state.

### 3.2 The TI Sigma multiplicative-threshold + consciousness-coupling hypothesis

Drug and supplement effects on the four-dimensional GILE state vector (G = Goodness, I = Intuition, L = Love, E = Environment) are mediated by:

- **Genetic substrate:** continuous FAAH activity (0.0 = full knockout, 1.0 = wild-type), COMT activity, CB1 receptor density.
- **Consciousness amplification factor:** `consciousness_amp = 1.0 + (schizotypy_snps / 100) × 0.5 + (cb1_density - 1.0) × 0.3 + (serotonin_sensitivity - 1.0) × 0.2` (per `TI_PHARMACOLOGICAL_SIMULATOR_EMPIRICAL_VALIDATION.md` §2.1.2).
- **L × E threshold structure (book Ch 18):** sub-threshold (L × E < 0.42), graded response (0.42 ≤ L × E ≤ 0.85), ceiling (L × E > 0.85).

### 3.3 Pre-registered predictions (the predictions this paper tests)

P1. The simulator gets the *direction* (sign) of GILE-dimension change correct on > 80% of independent validation experiments.
P2. The simulator gets the *magnitude* of GILE-dimension change within 2× of the empirical effect on > 60% of independent validation experiments.
P3. The simulator's mean TI/empirical ratio is calibrated to within ± 0.5 of unity (i.e., between 0.5 and 1.5).

[BRACKETED — Brandon to confirm: were these predictions formally pre-registered before the validation runs, or are they post-hoc-stated targets? If post-hoc, say so honestly per #69.]

## 4. Dataset

### 4.1 Source

The validation set consists of **12 hand-curated peer-reviewed pharmacological experiments** spanning rat, mouse, human RCT, and human case-study designs. Each experiment has a published citation and a stated empirical effect size in standard behavioral / clinical / biomarker units.

### 4.2 Inclusion criteria

- Pharmacological mechanism that maps to a TI Sigma simulator stack (i.e., the simulator must include a corresponding ingredient or genetic perturbation).
- A published peer-reviewed citation with quantified effect size.
- Behavioral / clinical endpoint mappable to one or more GILE dimensions per the GILE↔endpoint mapping table in §4.3.

### 4.3 GILE↔endpoint mapping table

| Behavioral / clinical endpoint | TI Sigma GILE dimension |
|---|---|
| Anxiolytic effect | GILE-L ↑ (reduced fear = expanded love bandwidth) |
| Antidepressant effect | GILE-L ↑ + GILE-G ↑ |
| Pro-social / affiliation maintained under stress | GILE-L ↑ + LCC ↑ |
| Fear extinction enhanced | GILE-G ↑ (right-action without fear-override) |
| Cognitive enhancement | GILE-I ↑ |
| Energy / anhedonia resistance | GILE-E ↑ |
| Stress resilience | GILE-G ↑ + GILE-L ↑ |

### 4.4 The twelve validation experiments

| # | Study | Citation | Effect | TI Stack |
|---|---|---|---|---|
| E01 | URB597 anxiolytic in EPM (rat) | Kathuria et al. 2003 Nat Med 9(1):76-81 | +62% open-arm time | curcubrain |
| E02 | FAAH-KO social resilience under CSDS (mouse) | Bluett et al. 2014 Nat Neurosci 17(4):571-576 | -37pp social avoidance | curcubrain + macamides |
| E03 | Anandamide BLA fear extinction (rat) | Morena et al. 2016 Neuropsychopharm 41(1):80-102 | +45% extinction | curcubrain + transdermal_cbd |
| E04 | PF-04457845 PTSD Phase 2 (human) | Huggins et al. 2012 Psychopharm 219(1):29-38 | -35% HAM-A | curcubrain + cbd + omega-3 |
| E05 | Jo Cameron FAAH-OUT (human, N=1) | Habib et al. 2019 Br J Anaesth 123(2):e249-253 | GAD-7 = 0, PHQ-9 = 0 | full FAAH stack |
| E06 | Saffron vs imipramine (human RCT) | Akhondzadeh et al. 2005 Phytother Res 19(2):148-151 | -62% HDRS | saffron_extract |
| E07 | 5-HTP vs fluvoxamine (human RCT) | Birdsall 1998 Altern Med Rev 3(4):271-280 | -62.6% HDRS | 5-HTP + B6 |
| E08 | L. helveticus + B. longum probiotic (human RCT) | Messaoudi et al. 2011 Benef Microbes 2(4):381-388 | -21% HADS, -21% cortisol | mood_probiotic |
| E09 | EPA-dominant omega-3 meta-analysis (14 trials, N=1497) | Su et al. 2015 J Clin Psychiatry | SMD -0.61 ≈ -27% HDRS | omega3_high_epa |
| E10 | L-methylfolate adjunctive in MTHFR variants | Papakostas et al. 2012 Am J Psychiatry 169(12):1267-1274 | +15.4 pp response, -23% HDRS | methylfolate + B6 |
| E11 | PQQ mitochondrial biogenesis + cognition | Harris et al. 2013 J Nutr Biochem 24(12):2076-2084 | +13% visual memory, -26% CRP | PQQ + CoQ10 |
| E12 | Ketamine + lithium synergy | Chiu et al. 2011 Expert Rev Mol Med 13:e32 | 1.4-1.7× synergy index, 2× duration | ketamine_troche + lithium |

### 4.5 Final dataset summary

| Statistic | Value |
|---|---|
| Number of experiments | 12 |
| Species | rat (3), mouse (1), human (8 — including 1 N=1 case study) |
| Therapeutic categories | anxiolytic, antidepressant, fear-extinction, antipsychotic-adjunctive, mitochondrial-cognitive, gut-brain-axis, rapid-antidepressant |
| Date of dataset freeze | 2026-04-30 (per `pharma_simulator_validation_report.md`) |

## 5. Feature Derivation: How Each Drug / Stack Gets a TI Sigma Prediction

### 5.1 The simulator core (`ti_pharmacological_simulator.py`)

A ~73 KB Python module (April 2026 build) that:

1. **Parses the input stack** — list of TI Sigma-recognized supplements/drugs with dosage and frequency.
2. **Fetches subject parameters** — genetic profile (FAAH activity, COMT, CB1, schizotypy SNP count), baseline GILE state (G, I, L, E, LCC, coherence).
3. **Computes anandamide-elevation multiplier** for FAAH-modulating components (per §2.1.1 of `TI_PHARMACOLOGICAL_SIMULATOR_EMPIRICAL_VALIDATION.md`):
   - Complete knockout (FAAH = 0): anandamide × 15 (per Cravatt et al.)
   - Heterozygous (FAAH = 0.5): × 3
   - Jo Cameron type (FAAH = 0.15): × 2
   - Supplement-induced: × (1 + faah_inhibition × nape_pld × cb1)
4. **Applies consciousness amplification** via the `consciousness_amp` formula in §3.2.
5. **Maps to GILE dimension changes** using stack-specific delta tables for L (love), G (goodness), I (intuition), E (energy/environment), LCC.
6. **Outputs:** ΔG, ΔI, ΔL, ΔE, ΔLCC; HEM-D2 Tralse meter; PD distribution (TT/TI/TF/DT/HEM); epilepsy-safety flags; interaction warnings.

### 5.2 Stack-to-mechanism mapping (illustrative subset)

| TI Stack ingredient | Mechanism | GILE channel |
|---|---|---|
| curcubrain | curcumin → FAAH inhibition + anti-neuroinflammatory | L ↑ via anandamide |
| macamides_5pct | maca macamides → FAAH inhibition + endocannabinoid tone | L ↑, LCC ↑ |
| transdermal_cbd | direct CBR + FAAH inhibition adjunct | L ↑, G ↑ via fear-extinction |
| saffron_extract | crocin → 5-HT reuptake inhibition + 5-HT2A modulation | L ↑ via serotonin |
| 5-HTP + B6 | direct serotonin precursor | L ↑ via serotonin synthesis |
| mood_probiotic | gut-brain axis via vagal afferents + GABA / SCFA production | L ↑ via gut-brain |
| omega3_high_epa | anti-inflammatory + neurotrophin (BDNF) modulation | L ↑ via membrane fluidity + BDNF |
| methylfolate + B6 | BH4 cofactor → neurotransmitter synthesis | G ↑, I ↑ |
| PQQ + CoQ10 | mitochondrial biogenesis | I ↑, E ↑ |
| ketamine_troche + lithium | NMDA antagonism + GSK-3β inhibition → AMPA/BDNF synergy | LCC ↑↑, G ↑, L ↑ |

### 5.3 Normalization

GILE dimensions are normalized to [0, 1]. Behavioral / clinical endpoints from the validation experiments are converted to "% of baseline" form (e.g., open-arm time +62% means baseline → 1.62 × baseline). The simulator's predicted ΔGILE is then expressed as "% of baseline GILE" for direct comparison.

## 6. Train / Held-Out Split

**The validation design is retrospective external validation, not a train/test split.** The simulator was built and parameterized BEFORE the 12 validation experiments were chosen as the validation set. The 12 experiments are independent published studies the simulator did not see during construction. This is arguably a stronger design than a within-dataset train/test split (no risk of split-leakage, no possibility of overfitting to the validation set), but it must be presented as such, not as "held-out" which carries train/test connotations.

[BRACKETED — Brandon to confirm: was every one of the 12 experiments selected AFTER the simulator was frozen, or were some used to inform parameter choice during simulator development? Per #69, any experiment that informed parameterization should be moved out of the validation set.]

## 7. Models

### 7.1 TI Sigma simulator (the thing being tested)

`ti_pharmacological_simulator.py` v2.0 (April 2026 build). See §5.

### 7.2 Linear-model baseline — STATUS: NOT YET COMPUTED

The book-body claim "vs ~46% for linear models" is **NOT substantiated** in the April 2026 validation report. To upgrade F-1 to VERIFIED, one of:

- **Option (a) — actually compute it:** Define a baseline as a logistic regression (or multinomial logit) on the FAAH-inhibition / serotonergic / mitochondrial pathway components → predicted GILE-L change. Evaluate on the same 12 experiments. Report directional + magnitude accuracy. If TI Sigma beats the baseline, report the actual margin (which may not be 35 pp).
- **Option (b) — remove the comparator:** Strike "vs ~46% for linear models" from the body claim until (a) is done. Replace with: "directional accuracy 100%, magnitude accuracy 83% within 2× — a level of performance that is non-trivial against the standard 40-60% individual-response prediction accuracy reported for population-statistics models."

[BRACKETED — Brandon to choose: (a) or (b).]

### 7.3 Other recommended baselines

- Random-classifier baseline (sanity check).
- Class-prior baseline (predict majority class always — for direction, this is "always +").
- Single-feature L-only baseline.

## 8. Evaluation

### 8.1 Primary metrics

- Directional accuracy: 12/12 = 100% (95% CI: Wilson ≈ [76%, 100%])
- Magnitude accuracy (within 2× of empirical): 10/12 = 83.3% (95% CI: Wilson ≈ [55%, 95%])
- Mean TI/empirical ratio: 1.20 (range 0.19 - 3.33)

### 8.2 Statistical-significance treatment

[NEEDS WRITE-UP] — Wilson CI on each accuracy figure (computed above). McNemar / sign-test against the baseline once §7.2 is resolved. Bootstrap CI on the mean TI/empirical ratio.

## 9. Results

### 9.1 Headline numbers (from `pharma_simulator_validation_report.md` Apr 30 2026)

| Metric | Value |
|---|---|
| Directional accuracy | 12/12 = 100.0% |
| Magnitude accuracy (within 2×) | 10/12 = 83.3% |
| Mean TI/empirical ratio | 1.20 (calibrated) |

### 9.2 Per-experiment results

See §4.4 table for citations + empirical effects; full per-experiment TI predictions and ratios in `pharma_simulator_validation_report.md` §"Individual Experiment Results".

### 9.3 Sub-claim results from `TI_PHARMACOLOGICAL_SIMULATOR_EMPIRICAL_VALIDATION.md` (Dec 2025)

A separate FAAH-pathway-narrow validation (against Cravatt 1996 FAAH-KO + Habib 2019 Jo Cameron) reports **98.2% accuracy** on anandamide elevation, hypothermia, and anxiety reduction. This is on a *different and narrower* set of metrics than §9.1 — should be reported as a separate sub-claim, not conflated with the 83.3% headline number.

## 10. Limitations (the #69 honest section)

- N = 12 is small. The Wilson 95% CI on 10/12 is quite wide [55%, 95%].
- Validation is hand-curated, not a random or systematic sample of the pharmacology literature. Selection bias risk: did Brandon preferentially curate experiments where the FAAH / serotonergic / mitochondrial mechanisms are best understood? If so, generalization beyond these mechanism classes is unsupported.
- No formally-computed linear-model baseline (see §7.2).
- The "82%" figure in the popular book corresponds to the 83.3% magnitude-accuracy here, rounded; the "vs 46% linear" comparator is currently unsubstantiated.
- The simulator's parameters were tuned to produce sensible behavior on the FAAH pathway during development; validation experiments E01-E05 are FAAH-pathway studies and should be treated with extra caution as cross-validation.
- Magnitude calibration is wide (TI/empirical ratios 0.19 - 3.33); the "within 2×" criterion is a loose magnitude criterion.

## 11. Code and Data Availability

- **Code:** `ti_pharmacological_simulator.py` + supporting modules (`brandon_pharmaco_gile_profile.py`, `pharma_tsc_predictor.py`, `pharma_simulator_validation.py`, `phase_a_prime_pharma_ablation.py`). To be deposited at Zenodo with commit hash.
- **Validation report:** `papers/pharma_simulator_validation_report.md` (April 30 2026).
- **Earlier FAAH-narrow validation:** `papers/TI_PHARMACOLOGICAL_SIMULATOR_EMPIRICAL_VALIDATION.md` (December 10 2025).
- **Prospective predictions (next phase):** `papers/pharmacological_predictions_brandon_2026.md` (12 prediction clusters for Brandon's stack).

## 12. Citation and License

- **Suggested citation:** Emerick, B. C. (2026). *TI Sigma: A Consciousness-Coupled Pharmacological Simulator with Retrospective Validation Against Twelve Peer-Reviewed Studies*. [Zenodo deposit forthcoming]. DOI: [to be assigned].
- **License:** CC BY 4.0 for text; MIT for code.

---

## Status of this skeleton (Pass 5)

Sections 4, 5, 9 now contain real specifics from the April 2026 validation. Sections 3.3 (pre-registration), 6 (split design), 7.2 (linear baseline), and 8.2 (significance tests) have explicit [BRACKETED] items requiring Brandon's ruling or computation work.

**Estimated effort to complete to VERIFIED status:** ~3-7 days of focused write-up + ~1-2 days of computational work (compute the linear baseline, run Wilson CIs, deposit code on Zenodo). The skeleton is now well-defined enough that the work is concrete, not open-ended.

**Single most important next step:** resolve §7.2 (linear baseline). Either compute it, or strike the comparator from the body claim per #69.
